Literature DB >> 26060190

Reversibility of neuropathology and motor deficits in an inducible mouse model for FXTAS.

Renate K Hukema1, Ronald A M Buijsen2, Martijn Schonewille3, Chris Raske4, Lies-Anne W F M Severijnen2, Ingeborg Nieuwenhuizen-Bakker2, Rob F M Verhagen2, Lisanne van Dessel2, Alex Maas5, Nicolas Charlet-Berguerand6, Chris I De Zeeuw7, Paul J Hagerman4, Robert F Berman8, Rob Willemsen2.   

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting carriers of the fragile X-premutation, who have an expanded CGG repeat in the 5'-UTR of the FMR1 gene. FXTAS is characterized by progressive development of intention tremor, ataxia, parkinsonism and neuropsychological problems. The disease is thought to be caused by a toxic RNA gain-of-function mechanism, and the major hallmark of the disease is ubiquitin-positive intranuclear inclusions in neurons and astrocytes. We have developed a new transgenic mouse model in which we can induce expression of an expanded repeat in the brain upon doxycycline (dox) exposure (i.e. Tet-On mice). This Tet-On model makes use of the PrP-rtTA driver and allows us to study disease progression and possibilities of reversibility. In these mice, 8 weeks of dox exposure was sufficient to induce the formation of ubiquitin-positive intranuclear inclusions, which also stain positive for the RAN translation product FMRpolyG. Formation of these inclusions is reversible after stopping expression of the expanded CGG RNA at an early developmental stage. Furthermore, we observed a deficit in the compensatory eye movements of mice with inclusions, a functional phenotype that could be reduced by stopping expression of the expanded CGG RNA early in the disease development. Taken together, this study shows, for the first time, the potential of disease reversibility and suggests that early intervention might be beneficial for FXTAS patients.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26060190      PMCID: PMC4527492          DOI: 10.1093/hmg/ddv216

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

1.  A comparison of video and magnetic search coil recordings of mouse eye movements.

Authors:  J S Stahl; A M van Alphen; C I De Zeeuw
Journal:  J Neurosci Methods       Date:  2000-06-30       Impact factor: 2.390

Review 2.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

Review 3.  Epidemiology of fragile X syndrome: a systematic review and meta-analysis.

Authors:  Jessica Hunter; Oliver Rivero-Arias; Angel Angelov; Edward Kim; Iain Fotheringham; Jose Leal
Journal:  Am J Med Genet A       Date:  2014-04-03       Impact factor: 2.802

4.  Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS).

Authors:  C M Greco; R F Berman; R M Martin; F Tassone; P H Schwartz; A Chang; B D Trapp; C Iwahashi; J Brunberg; J Grigsby; D Hessl; E J Becker; J Papazian; M A Leehey; R J Hagerman; P J Hagerman
Journal:  Brain       Date:  2005-12-05       Impact factor: 13.501

5.  The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.

Authors:  Rob Willemsen; Marianne Hoogeveen-Westerveld; Surya Reis; Joan Holstege; Lies-Anne W F M Severijnen; Ingeborg M Nieuwenhuizen; Mariette Schrier; Leontine van Unen; Flora Tassone; Andre T Hoogeveen; Paul J Hagerman; Edwin J Mientjes; Ben A Oostra
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

6.  Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo.

Authors:  Renate K Hukema; Ronald A M Buijsen; Chris Raske; Lies Anne Severijnen; Ingeborg Nieuwenhuizen-Bakker; Michelle Minneboo; Alex Maas; Rini de Crom; Johan M Kros; Paul J Hagerman; Robert F Berman; Rob Willemsen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Ectopic expression of CGG containing mRNA is neurotoxic in mammals.

Authors:  Vera Hashem; Jocelyn N Galloway; Mayra Mori; Rob Willemsen; Ben A Oostra; Richard Paylor; David L Nelson
Journal:  Hum Mol Genet       Date:  2009-04-18       Impact factor: 6.150

8.  Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model.

Authors:  Ali Entezam; Rea Biacsi; Bonnie Orrison; Tapas Saha; Gloria E Hoffman; Ed Grabczyk; Robert L Nussbaum; Karen Usdin
Journal:  Gene       Date:  2007-03-16       Impact factor: 3.688

9.  FMRpolyG-positive inclusions in CNS and non-CNS organs of a fragile X premutation carrier with fragile X-associated tremor/ataxia syndrome.

Authors:  Ronald A M Buijsen; Chantal Sellier; Lies-Anne W F M Severijnen; Mustapha Oulad-Abdelghani; Rob F M Verhagen; Robert F Berman; Nicolas Charlet-Berguerand; Rob Willemsen; Renate K Hukema
Journal:  Acta Neuropathol Commun       Date:  2014-11-26       Impact factor: 7.801

Review 10.  RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disorders.

Authors:  Marzena Wojciechowska; Marta Olejniczak; Paulina Galka-Marciniak; Magdalena Jazurek; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2014-09-12       Impact factor: 16.971

View more
  25 in total

Review 1.  What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Authors:  Molly M Foote; Milo Careaga; Robert F Berman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

2.  Repeat-associated non-ATG (RAN) translation.

Authors:  John Douglas Cleary; Amrutha Pattamatta; Laura P W Ranum
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

Review 3.  [Fragile X associated tremor/ataxia syndrome: its clinical presentation, pathology, and treatment].

Authors:  M J Salcedo-Arellano; R J Hagerman; V Martinez-Cerdeno
Journal:  Rev Neurol       Date:  2019-03-01       Impact factor: 0.870

4.  A Majority of FXTAS Cases Present with Intranuclear Inclusions Within Purkinje Cells.

Authors:  Jeanelle Ariza; Hailee Rogers; Angela Monterrubio; Adriana Reyes-Miranda; Paul J Hagerman; Verónica Martínez-Cerdeño
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

5.  Selective rescue of heightened anxiety but not gait ataxia in a premutation 90CGG mouse model of Fragile X-associated tremor/ataxia syndrome.

Authors:  Hoanna Castro; Emre Kul; Ronald A M Buijsen; Lies-Anne W F M Severijnen; Rob Willemsen; Renate K Hukema; Oliver Stork; Mónica Santos
Journal:  Hum Mol Genet       Date:  2017-06-01       Impact factor: 6.150

Review 6.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

Review 7.  RAN translation-What makes it run?

Authors:  Katelyn M Green; Alexander E Linsalata; Peter K Todd
Journal:  Brain Res       Date:  2016-04-06       Impact factor: 3.252

Review 8.  Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Motor Dysfunction Modeled in Mice.

Authors:  Molly Foote; Gloria Arque; Robert F Berman; Mónica Santos
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

9.  Presence of inclusions positive for polyglycine containing protein, FMRpolyG, indicates that repeat-associated non-AUG translation plays a role in fragile X-associated primary ovarian insufficiency.

Authors:  R A M Buijsen; J A Visser; P Kramer; E A W F M Severijnen; M Gearing; N Charlet-Berguerand; S L Sherman; R F Berman; R Willemsen; R K Hukema
Journal:  Hum Reprod       Date:  2015-11-03       Impact factor: 6.918

10.  Translation of GGC repeat expansions into a toxic polyglycine protein in NIID defines a novel class of human genetic disorders: The polyG diseases.

Authors:  Manon Boivin; Jianwen Deng; Véronique Pfister; Erwan Grandgirard; Mustapha Oulad-Abdelghani; Bastien Morlet; Frank Ruffenach; Luc Negroni; Pascale Koebel; Hugues Jacob; Fabrice Riet; Anke A Dijkstra; Kathryn McFadden; Wiley A Clayton; Daojun Hong; Hiroaki Miyahara; Yasushi Iwasaki; Jun Sone; Zhaoxia Wang; Nicolas Charlet-Berguerand
Journal:  Neuron       Date:  2021-04-21       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.